🔥Telegram İfşa

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma. #AJH Mayo Clinic Comprehensive Cancer Center 10 Tables; Algorithms Includes current data including trials published this month! #ASCO24 onlinelibrary.wiley.com/doi/10.1002/aj…

Evans syndrome is a rare disease marked by a severe clinical course and sometimes fatal outcome. Management is highly heterogeneous. ICYMI: first consensus recommendations for the diagnosis and management of Evans syndrome in adults thelancet.com/journals/lanha…

Octogenarians and nonagenarians with AML can be treated successfully with VEN-HMA, and a subset of patients (∼25%) have prolonged survival. ow.ly/VLjE50SMLAz #myeloidneoplasia #acutemyeloidleukemia

British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/abs/10.111…

Publication in Blood Advances featuring Toyosi Odenike and Wendy Stock as part of the BEAT-AML initiative! ashpublications.org/bloodadvances/…

K/L FLC ratio unlocked Roger Rodby #GlomConHawaii GlomCon

Just published in British Journal of Haematology - an updated BSH - Haematology good practice paper on the ever-controversial topic of CNS prophylaxis in LBCL! Pleasure to work with Kate Cwynarski Toby Eyre Jeff Smith Sridhar Chaganti @DrChrisPFox and Pam McKay on this... 1/2 onlinelibrary.wiley.com/doi/10.1111/bj…

Thrombophilia management calculator ow.ly/Gag750SWYKm #healthservicesandoutcomes #thrombosisandhemostasis

NPM1-mutated AML: how many diseases? ow.ly/lpCI50SYJLV #clinicaltrialsandobservations

New ⁦National Comprehensive Cancer Network (NCCN)⁩ guidelines for Breast/Ovarian/Pancreatic Cancer Genetics posted at nccn.org/professionals/… New recommendation that #PancreaticCancer screening be “considered” for all BRCA2 and ATM pathogenic variant carriers by age 50, even without known family history

New article with Wendy Stock as co-author presenting results from an early-phase trial of dasatinib plus asciminib in Ph+ ALL! pubmed.ncbi.nlm.nih.gov/39374521/

Baystate past and present residents, fellows and faculty got together at #ASH24. How wonderful to see everyone together!

For decades, the only option for newly diagnosed acute myelogenous leukemia #AML that provided a path to remission and long-term disease-free survival required initial treatment with intensive induction therapy. ow.ly/XexH50VlQY6

Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine nejm.org/doi/full/10.10…

Of the 12 patients who reversed from MRD negative to MRD positive and restarted maintenance, 4 progressed and all remained alive. ow.ly/7kkM50VTAg9 #lymphoidneoplasia #multiplemyeloma

Original Article: Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma (MIDAS phase 3 trial) nej.md/4mkaecR #ASCO25 | ASCO

#Myeloma Paper of the Day: MIDAS study of MRD-guided consolidation strategy in pts eligible for ASCT finds those who were MRD-negative @ 10-5 post-induction % w/ pre-maintenance MRD- status at 10-6 sensitivity was not higher with ASCT vs. Isa-KRd: pubmed.ncbi.nlm.nih.gov/40459097/. #mmsm

David Scott’s BC Cancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML Ash Alizadeh, MD/PhD 🇺🇸

Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence evidence.nejm.org/doi/full/10.10…